Femasys (NASDAQ:FEMY) Releases Quarterly Earnings Results

Femasys (NASDAQ:FEMY) released its quarterly earnings results on Tuesday. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04), Zacks reports. The company had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 120.13%.

Femasys Trading Up 0.5 %

Shares of Femasys stock traded up $0.01 on Wednesday, hitting $1.04. The company had a trading volume of 274,081 shares, compared to its average volume of 333,511. The company has a debt-to-equity ratio of 0.43, a quick ratio of 5.93 and a current ratio of 6.47. The stock has a 50 day moving average of $1.16 and a 200-day moving average of $1.15. Femasys has a 1 year low of $0.73 and a 1 year high of $2.40.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Femasys in a report on Tuesday. Chardan Capital reduced their target price on shares of Femasys from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.